Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2017

The Pharma Closeout tracks 47 deals, $164.4B in disclosed deal value, 39 with a post-close Outcome Score for the year 2017.

Median Critic Score: 75  ·  Median Outcome Score: 59

Best outcome: Novartis AG / Advanced Accelerator Applications S.A. (98)  ·  Weakest outcome: Mallinckrodt plc / InfaCare Pharmaceutical Corporation (12)

All 47 deals

• Novartis AG / Advanced Accelerator Applications S.A. — 2017 · $3.9B · Worked — the deal delivered on its rationale.
• Johnson & Johnson (Janssen Biotech Inc.) / Legend Biotech Corporation — 2017 · $9.0B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Actelion Ltd — 2017 · $30.0B · Worked — the deal delivered on its rationale.
• Pamplona Capital Management, LLP / PAREXEL International Corporation — 2017 · $5.0B · Worked — the deal delivered on its rationale.
• Thermo Fisher Scientific Inc. / Patheon N.V. — 2017 · $7.2B · Worked — the deal delivered on its rationale.
• PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG — 2017 · $1.3B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / AstraZeneca PLC — 2017 · $8.5B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. — 2017 · $250M · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Legend Biotech Corporation — 2017 · $350M · Worked — the deal delivered on its rationale.
• Bain Capital Private Equity / Cinven Partners (Nidda Healthcare Holding AG) / STADA Arzneimittel AG — 2017 · $6.1B · Worked — the deal delivered on its rationale.
• Becton, Dickinson and Company / C.R. Bard Inc. — 2017 · $24.0B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Halozyme Therapeutics, Inc. — 2017 · $190M · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Bristol-Myers Squibb Company — 2017 · $625M · Largely worked — most objectives met.
• Roche Holding AG / Ignyta Inc. — 2017 · $1.7B · Largely worked — most objectives met.
• Sanofi SA / Protein Sciences Corp. — 2017 · $650M · Largely worked — most objectives met.
• Incyte Corporation / MacroGenics, Inc. — 2017 · $900M · Largely worked — most objectives met.
• Gilead Sciences Inc. / Kite Pharma Inc. — 2017 · $11.9B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company (via Celgene Corporation) / Dragonfly Therapeutics Inc. — 2017 · $475M · Largely worked — most objectives met.
• Eli Lilly and Company / AC Immune SA — 2017 · $2.0B · Mixed — partial payoff, real shortfalls.
• Astellas Pharma Inc. / Ogeda SA — 2017 · $850M · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Eisai Co., Ltd. — 2017 · $5.8B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / CoLucid Pharmaceuticals — 2017 · $960M · Mixed — partial payoff, real shortfalls.
• Bioverativ Inc. / True North Therapeutics, Inc. — 2017 · $825M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Limited / TESARO, Inc. — 2017 · $340M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Limited / ARIAD Pharmaceuticals, Inc. — 2017 · $5.2B · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Agenus Inc. — 2017 · $1.6B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Ablynx NV — 2017 · $2.7B · Underwhelmed — fell short of the thesis.
• Mitsubishi Tanabe Pharma Corporation / NeuroDerm Ltd. — 2017 · $1.1B · Underwhelmed — fell short of the thesis.
• Incyte Corporation / Merus N.V. — 2017 · $3.0B · Underwhelmed — fell short of the thesis.
• Allergan plc / Zeltiq Aesthetics, Inc. — 2017 · $2.5B · Underwhelmed — fell short of the thesis.
• Novartis AG / Agenus Inc. — 2017 · $2.6B · Underwhelmed — fell short of the thesis.
• Bristol-Myers Squibb Company / IFM Therapeutics, LLC — 2017 · $2.3B · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. (via Kite Pharma) / Cell Design Labs, Inc. — 2017 · $567M · Did not work — the deal failed to deliver.
• Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. — 2017 · $1.2B · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Pieris Pharmaceuticals, Inc. — 2017 · $2.2B · Did not work — the deal failed to deliver.
• CSL Behring (CSL Limited) / Calimmune, Inc. — 2017 · $416M · Did not work — the deal failed to deliver.
• Biogen Inc. / Bristol-Myers Squibb Company — 2017 · $710M · Did not work — the deal failed to deliver.
• Mallinckrodt plc / InfaCare Pharmaceutical Corporation — 2017 · $425M · Did not work — the deal failed to deliver.
• Hologic, Inc. / Cynosure, Inc. — 2017 · $1.6B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Halozyme Therapeutics, Inc. — 2017 · $1.9B
• Servier (Les Laboratoires Servier SAS) / Pieris Pharmaceuticals, Inc. — 2017 · $1.7B
• Bayer AG / Loxo Oncology, Inc. — 2017 · $1.6B
• Pfizer Inc. / Sangamo Therapeutics, Inc. — 2017 · $545M
• Fresenius Kabi AG / Akorn, Inc. — 2017 · $4.8B
• Janssen Pharmaceuticals (Johnson & Johnson) / PeptiDream Inc. — 2017 · $1.1B
• Merck KGaA / Vertex Pharmaceuticals Incorporated — 2017 · $1.2B
• Incyte Corporation / Calithera Biosciences, Inc. — 2017 · $803M

← Deal Library  ·  Interactive search  ·  How we score deals